TY - JOUR
T1 - Clinical practice guidelines in oncology
AU - Kumar, Shaji K.
AU - Callander, Natalie S.
AU - Alsina, Melissa
AU - Atanackovic, Djordje
AU - Biermann, J. Sybil
AU - Chandler, Jason C.
AU - Costello, Caitlin
AU - Faiman, Matthew
AU - Fung, Henry C.
AU - Gasparetto, Cristina
AU - Godby, Kelly
AU - Hofmeister, Craig
AU - Holmberg, Leona
AU - Holstein, Sarah
AU - Huff, Carol Ann
AU - Kassim, Adetola
AU - Liedtke, Michaela
AU - Martin, Thomas
AU - Omel, James
AU - Raje, Noopur
AU - Reu, Frederic J.
AU - Singhal, Seema
AU - Somlo, George
AU - Stockerl-Goldstein, Keith
AU - Treon, Steven P.
AU - Weber, Donna
AU - Yahalom, Joachim
AU - Shead, D. A.
AU - Kumar, Rashmi
N1 - Publisher Copyright:
©copy;JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.
AB - Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.
KW - Antineoplastic Agents/supply & distribution
KW - Antineoplastic Combined Chemotherapy Protocols/standards
KW - Asymptomatic Diseases
KW - Chemotherapy, Adjuvant/methods
KW - Humans
KW - Immunoglobulins/blood
KW - Magnetic Resonance Imaging
KW - Maintenance Chemotherapy/methods
KW - Medical Oncology/standards
KW - Multiple Myeloma/blood
KW - Myeloma Proteins/analysis
KW - Positron Emission Tomography Computed Tomography
KW - Radiotherapy, Adjuvant/methods
KW - Serologic Tests
KW - Standard of Care
KW - Stem Cell Transplantation/methods
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85016214542&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2017.0023
DO - 10.6004/jnccn.2017.0023
M3 - Article
C2 - 28188192
AN - SCOPUS:85016214542
SN - 1540-1405
VL - 15
SP - 230
EP - 269
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 2
ER -